NorthWest Biotherapeutics Inc (NWBO)

[Umibe5690]

I agree with your analysis. One thing that I have not been able to reconcile is the non-methylated presentation result as compared with the non-methylated interim blind/blended data.

As you know, in the JTM article, SOC mOS for non-methylated was 12.7 months and blended results as per the interim data was 19.8 months, which is a delta of 7 months. Adjusting for randomization, there still is a delta of 4 months. However, the presentation results show a negligible delta, if any at all, of any significance.

The 13% survival tail was less than the interim article would have suggested at or about 20% and not as robust due to the negligible, if any, efficacy wrt non-methylated.